This agenda has been prepared to provide information regarding the upcoming meeting and is subject to change.
Main Menu
Friday, October 6
7:30 AM
YIM Continental Breakfast
8:00 AM
Young Investigator Meeting
6:30 PM
iwCLL Welcome Reception
Saturday, October 7, 2023
7:15 AM
Continental Breakfast
8:15 AM
Welcome and Introductions
Jennifer Brown, MD, PhD
8:30 AM
Honoring the Past: In Memoriam and 20 Years of iwCLL
Session 1: Integrative Aspects of Genomics
Session Co-Chairs: Christopher Oakes, MD, PhD & Gad A. Getz, PhD
8:40 AM
Multiomic Integration in CLL
Cynthia K. Hahn, MD
8:55 AM
Whole-Genome Analysis of CLL and Interplay of Coding, Non-Coding, Transcriptome and Epigenetic Events
Pauline Robbe, PhD
9:10 AM
Genomics of Richter Transformation: Part I
Ferran Nadeu, PhD
9:20 AM
Genomics of Richter Transformation: Part II
Erin Parry, MD, PhD
9:30 AM
Commentary on Each Other’s Work and Consensus Regarding the Genomics and Richter’s Transformation
Ferran Nadeu, PhD and Erin Parry, PhD
9:40 AM
Panel Discussion With Interactivity and Audience Q&A
9:50 AM
*SF3B1 mutation and ATM deletion co-drive leukemogenesis via centromeric R-loop dysregulation
Lili Wang, MD, PhD
10:00 AM
*Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
Qu Jiang, PhD
10:10 AM
Morning Break
Session 2: Proteomics and Metabolism of CLL
Session Co-Chairs: Catherine Wu, MD & Jennifer Abelin, PhD
10:35 AM
Influence of Metabolism on Leukemia Progression
Matthew Vander Heiden, MD, PhD
10:50 AM
Proteogenomic Characterization of CLL and Drug Response/Resistance
Sascha Dietrich, MD
11:05 AM
CLL Proteomics and Immunoproteomics
Catherine Wu, MD
11:20 AM
*Targeting translation initiation as novel therapeutic in CLL
Etienne Moussay, PhD
11:30 AM
*METTL3 contributes to aggressive CLL via post-transcriptional regulation of splicing factor
Lili Wang, MD, PhD
11:40 AM
*TRAF3 inactivation in chronic lymphocytic leukemia enhances metabolic cellular plasticity through metabolic reprogramming and associates with adverse prognosis
Claudia Pérez Carretero, PhD
11:50 AM
Panel Discussion With Interactivity and Audience Q&A
12:05 PM
Lunch
12:55 PM
Industry Supported Symposium
Session 3: Microenvironment and Pre-Clinical Immunotherapies
Anti-Tumor Immunity in the Lymphoid Microenvironment
Martina Seiffert, PhD
2:10 PM
The Tumor Supportive Microenvironment of CLL
Jérôme Paggetti, PhD
2:25 PM
Modeling the Tumor Microenvironment of CLL In Vitro
Cristina Scielzo, PhD
2:35 PM
The Tumor Microenvironment and Genetic Heterogeneity of CLL
Clare Sun, MD
2:45 PM
Panel Discussion With Interactivity and Audience Q&A
3:05 PM
*Constitutive VLA-4 activation is linked to BCR autonomous signaling in circulating CLL cells and promotes pro-survival signals through soluble blood-borne VCAM-1 binding
Erika Tissino, PhD
3:15 PM
*Exploiting the modulation of FOXO1 signaling as a therapeutic target in CLL through combination of ERK and BTK inhibition
Jodie F. Hay, PhD
3:25 PM
Afternoon Break
Session 4: Debate and Roundtable – How Do We Define Success in CLL?
Session Co-Chairs: John Seymour, MBBS, PhD & Lydia Scarfò, PhD
3:50 PM
*Does the Life Expectancy of Elderly CLL Patients Receiving Upfront Targeted Agents Approach the Life Expectancy of the General Population?
Stefano Molica, MD
4:00 PM
Multiparty “Statement of Perspective”
Michele Nadeem Baker Danielle Brander, MD Barbara Eichhorst, MD Carsten Niemann, MD, PhD William Wierda, MD, PhD
4:35 PM
Panel Discussion With Interactivity and Audience Q&A
Updated Perspective on Time-Limited Venetoclax + Obinutuzumab
Othman Al-Sawaf, MD
8:45 AM
Current and Future Use of BTKi + BCL-2i Combinations
Nitin Jain, MD
9:00 AM
Panel Discussion With Interactivity and Audience Q&A
9:15 AM
Trials in Progress
9:15 AM
*Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group
Florian Simon, MD
9:25 AM
*Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk: interim results of MRD kinetics in the ERADIC trial from the FILO group
Anne-Sophie Michallet, MD, PhD
9:35 AM
*Bruton tyrosine kinase inhibitor ibrutinib induces hypertension by upregulating transcription of CaV1.2 calcium channel
Juejin Wang, MD, PhD
9:45 AM
*Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment
Andy Rawstron, PhD
9:55 AM
Morning Break
10:20 AM
Industry Supported Symposium
Session 6: Mechanisms of Resistance
Session Co-Chairs: Jennifer Woyach, MD & Marek Mráz, PhD
11:20 AM
Resistance to Covalent BTKi
Adrian Wiestner, MD, PhD
11:35 AM
Resistance to Non-Covalent BTKi
Varsha Gandhi, MD
11:50 AM
Resistance to BCL2i
Rachel Thijssen, PhD
12:05 PM
*Bruton’s Tyrosine Kinase and Phospholipase C-Gamma 2 Mutational Profiles in Pooled Analysis of Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Inhye Ahn, MD
12:15 PM
*Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia (CLL)
Kiyomi Mashima, MD, PhD
12:25 PM
*Recurrent Genomic Alterations in the Apoptotic Machinery in Patients With CLL Treated With Venetoclax Monotherapy Following Treatment With BCRi
Jennifer Woyach, MD
12:35 PM
**Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Jennifer Brown, MD, PhD
12:40 PM
Panel Discussion With Interactivity and Audience Q&A
12:55 PM
Lunch
1:45 PM
Industry Supported Symposium
Session 7: Future Directions for the Treatment of Relapsed/Refractory CLL
*Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results From the Phase 1b/2 EPCORE CLL-1 Trial Expansion Cohort
Arnon Kater, MD, PhD
2:55 PM
*Bendamustine, Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of the CLL2-BAAG Trial of the German CLL Study Group (GCLLSG)
Paula Cramer, MD
3:05 PM
**Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
John F. Seymour, MBBS, FRACP, PhD
3:10 PM
**Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Tanya Siddiqi, MD
3:15 PM
BTK Degraders – From Bench To Bedside
Alexey Danilov, MD, PhD
3:25 PM
Novel Inducers of Apoptosis
Deepa Sampath, PhD
3:35 PM
How to Overcome T-Cell Dysfunction: Bispecifics
Arnon Kater, MD, PhD
3:45 PM
How to Overcome T-Cell Dysfunction: Cellular Therapies
Jos Melenhorst, PhD
3:55 PM
Panel Discussion with Interactivity and Audience Q&A
General Management of CLL patients from a Vaccine and Prophylaxis Standpoint
Carolyn Owen, MD
10:30 AM
What Can We Learn from COVID-19 About Immune Dysfunction and Risk of Infections in CLL?
Yair Herishanu, MD
10:45 AM
CLL Vaccine Responsiveness
Chris Pleyer, MD
11:00 AM
Panel Discussion with Interactivity and Audience Q&A
11:15 AM
*Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with targeted drugs: pooled analysis of clinical trials from the German CLL Study Group (GCLLSG)
Elia Boccellato, MD
11:25 AM
*Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia
Randall S. Davis, MD
11:35 AM
Industry Supported Symposium
12:35 PM
Lunch
1:25 PM
Keynote Anticipated Role of AI/Machine Learning in Research and Treatment of CLL and Other Malignancies
Mihaela van der Schaar, PhD
Session 10: Global Perspective on CLL Management – Real World Data and Patient Experiences
Session Co-Chairs: Anna Schuh, MD, PhD & Pat Garcia-Gonzalez
1:55 PM
Special Announcement From the iwCLL
Anna Schuh, MD, PhD
2:00 PM
The Impact of the War on Management of Patients with CLL in Ukraine: What can the iwCLL do to Mitigate Impact in Short and Longer Term
Iryna Kriachok, PhD
2:10 PM
Managing Patients with CLL from Different Socio-Economic Backgrounds in Argentina
Miguel Pavlovsky, MD
2:20 PM
Update on the iwCLL Capacity Building Pilot Program in Tanzania
William Frank Mawalla, MD
2:30 PM
Challenges of Diagnosis and Management of Patients with CLL in South Korea
Ja Min Byun, MD, PhD
2:40 PM
Trial Updates from China
Shenmiao Yang, MD
2:50 PM
Global Survey Results from the CLL Advocates Network
Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd
3:00 PM
*A high proportion of IGHV4-39, subset #8 and #8B in Chinese patients with chronic lymphocytic leukemia: a retrospective analysis of 3154 Ig VH sequences by cwCLL, Chinese workshop on CLL
Yi Xia, MD
3:10 PM
Panel Discussion With Interactivity and Audience Q&A
3:25 PM
Afternoon Break
Session 11: Past, Present, and Future of CLL
Session Chair: Jennifer R. Brown, MD, PhD
3:50 PM
Future Research Priorities and Unmet Needs in CLL: A Roundtable Discussion and Audience Q&A
Jennifer R. Brown, MD, PhD
Florence Cymbalista, MD, PhD
Matthew Davids, MD, MMSc
Paolo Ghia, MD, PhD
Thomas J. Kipps, MD, PhD
Susan O’Brien, MD